NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James Sterling, with a grant date of July 1, 2024. The stock options approved under the Inducement Plan have an...
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation ...
Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.
CHICAGO , June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy. 2Fl...
Gene therapy maker bluebird bio on Wednesday named former Renalytix finance chief James Sterling as its CFO to oversee the revision of the company's financial statements.
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. “We are thrilled to welcome James to bluebird bio. We are con...
BENSALEM, Pa. , May 22, 2024 /PRNewswire/ -- Law Offices of Howard G.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.